RedHill Biopharma Ltd.RDHLNASDAQ
Loading
EPS Growth Under PressureDecelerating
Percentile Rank41
Year-over-Year Change
Year-over-year earnings per share growth rate
Latest
0.00%
↓ 100% vs avg
Percentile
P41
Within normal range
Average
10.80%
Historical baseline
| Period | Value |
|---|---|
| Q2 2025 | 0.00% |
| Q1 2025 | 0.00% |
| Q4 2024 | 0.00% |
| Q3 2024 | 0.00% |
| Q2 2024 | 0.00% |
| Q1 2024 | 94.12% |
| Q4 2023 | 29.17% |
| Q3 2023 | -900.00% |
| Q2 2023 | -98.83% |
| Q1 2023 | 1380.00% |
| Q4 2022 | 92.91% |
| Q3 2022 | -173.79% |
| Q2 2022 | 47.18% |
| Q1 2022 | 20.08% |
| Q4 2021 | -7.02% |
| Q3 2021 | 26.92% |
| Q2 2021 | -17.29% |
| Q1 2021 | 16.09% |
| Q4 2020 | -26.80% |
| Q3 2020 | -11.61% |
| Q2 2020 | 7.82% |
| Q1 2020 | -47.27% |
| Q4 2019 | 4.62% |
| Q3 2019 | 9.90% |
| Q2 2019 | -10.34% |
| Q1 2019 | -28.89% |
| Q4 2018 | 36.92% |
| Q3 2018 | 17.69% |
| Q2 2018 | -11.59% |
| Q1 2018 | 6.80% |
| Q4 2017 | 44.69% |
| Q3 2017 | -40.81% |
| Q2 2017 | -26.88% |
| Q1 2017 | 21.91% |
| Q4 2016 | 7.69% |
| Q3 2016 | -36.58% |
| Q2 2016 | -18.43% |
| Q1 2016 | 17.49% |
| Q4 2015 | -40.64% |
| Q3 2015 | 46.57% |